4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

SCHEDULE 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

S-8 - Astria Therapeutics, Inc. (0001454789) (Filer)

10-Q - Astria Therapeutics, Inc. (0001454789) (Filer)

8-K - Astria Therapeutics, Inc. (0001454789) (Filer)

SCHEDULE 13G - Astria Therapeutics, Inc. (0001454789) (Subject)

8-K - Astria Therapeutics, Inc. (0001454789) (Filer)

10-Q - Astria Therapeutics, Inc. (0001454789) (Filer)

SCHEDULE 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

DEFA14A - Astria Therapeutics, Inc. (0001454789) (Filer)

DEF 14A - Astria Therapeutics, Inc. (0001454789) (Filer)

H.C. Wainwright reiterated coverage of Astria Therapeutics with a rating of Buy and set a new price target of $20.00 from $16.00 previously

Cantor Fitzgerald initiated coverage of Astria Therapeutics with a rating of Overweight and set a new price target of $47.00

JMP Securities initiated coverage of Astria Therapeutics with a rating of Mkt Outperform and set a new price target of $26.00

TD Cowen initiated coverage of Astria Therapeutics with a rating of Buy and set a new price target of $35.00

Evercore ISI initiated coverage of Astria Therapeutics with a rating of Outperform and set a new price target of $18.00

Jefferies initiated coverage of Astria Therapeutics with a rating of Buy and set a new price target of $20.00

SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

SC 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)

SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

SC 13G - Astria Therapeutics, Inc. (0001454789) (Subject)

SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

-- Results Support Potential for STAR-0310 to be Best-in-Class OX40 Antagonist -- -- STAR-0310 Exhibits Longest-in-Class Half-Life of 68 Days and Cytokine Suppression Lasting At Least 20 Weeks After a Single 300 mg SC Injection, Supporting Potential Every-Six-Month Administration -- -- STAR-0310 Was Well-Tolerated, with no ADCC-Related Treatment-Emergent Adverse Events, Supporting a Wider Therapeutic Window with the Potential to Drive Greater Efficacy than First-Generation OX40 Antibodies -- -- Results to be Presented by Dr. Stephan Weidinger, M.D., Ph.D. on September 18, at 4:00pm CEST -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing lif

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 128,000 shares of Astria's common stock on September 2, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted as an inducement material to three employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $6.59, which is equal to the closing price of

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial data from the Phase 1a trial of STAR-0310 at the European Academy of Dermatology & Venereology (EADV) Congress 2025, taking place September 17-20, 2025 in Paris, France. Stephan Weidinger, M.D., Ph.D., Director and Chair of the Department of Dermatology and Allergy at the University Medical Center Kiel, Schleswig-Holstein, will present initial results from the Phase 1a trial of STAR-0310 in healthy participants in a late-breaking oral presentation titled, "Demonstration of Early Proof-of-Conce

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Thursday, September 4 at 3:20pm ET. A webcast of the presentation can be accessed at the following link: https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=98838667&checkCompany=1&checkEmail=1&checkName=1. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event

-- Kaken Pharmaceutical, Co., Ltd. Will Pay Astria Therapeutics Up to $32 Million in Upfront and Milestone Payments, Plus Royalties for Japanese Development and Commercialization Rights Related to Navenibart -- -- Updated Cash Runway Supports the Company's Operating Plan into 2028 -- -- ALPHA-ORBIT, A Pivotal Phase 3 Trial Evaluating Every 3- and Every 6-Month Administration of Navenibart (STAR-0215) in Hereditary Angioedema, is Enrolling Patients with Topline Data Anticipated in Early 2027-- -- STAR-0310, an OX40 inhibitor in Development for Atopic Dermatitis, Expected to Report Initial Phase 1a Healthy Subject Results in Q3 2025 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biop

-- Up to $32 Million in Upfront and Milestone Payments, Plus Royalties -- -- Kaken Expertise in Commercializing Innovative Therapies Supports Navenibart's Potential to be First-Choice HAE Treatment in Japan -- -- Updated Cash Runway Supports the Company's Operating Plan Into 2028 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it has exclusively licensed development and commercialization rights in Japan to Kaken Pharmaceutical, Co., Ltd., a Japanese specialty pharmaceutical company, for navenibart, a long-acting investigational monoclonal antibody inhibitor

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 180,000 shares of Astria's common stock on August 1, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted as an inducement material to two employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $6.56, which is equal to the closing price of Astr

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four posters at the 2025 US Hereditary Angioedema Association (HAEA) National Summit, taking place July 10-13, 2025 in Baltimore, Maryland. Timothy Craig, D.O., Professor of Medicine, Pediatrics, and Biomedical Sciences at Penn State University in Hershey, Pennsylvania, will present information on the global Phase 3 trial of navenibart in an encore presentation of poster number 2 titled, "ALPHA-ORBIT - a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 119,860 shares of Astria's common stock on July 1, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted as an inducement material to six employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $5.43, which is equal to the closing price of Astria

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will participate in a panel discussion at the Oppenheimer Innovators in Immunology & Inflammation (I&I) Summit on June 25 in New York, NY. Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a panel titled, "Advances in Dermatology: AD and CSU" on Wednesday, June 25 at 10:45am ET. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program,

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience. "It is a pleasure to welcome Sunil to our Board of Directors," said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. "His extensive drug development and clinical expertise strongly complements our Board's skills and experiences, and we look forward to his contributions as we continue to advance our programs into later-stage cl

-- STAR-0215 Dosed Once or Twice Over 6 Months Reduced Monthly Attack Rates by 90-96%, Supporting Chronic Dosing 2 or 4 Times Per Year -- -- 92-100% Decrease in Moderate or Severe Attacks and 91-95% Reduction in Attacks Requiring Rescue Medications with STAR-0215 -- -- Very Well-Tolerated with No Serious Adverse Events and No Discontinuations -- -- Phase 3 Initiation on Track for Q1 2025, with Top-Line Results Expected by Year End 2026 -- -- Current Cash Expected to Fund Company into Mid-2027 -- -- Conference Call Today at 8:30am ET – Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, will report third quarter 2023 financial results before the Nasdaq Global Market open on Monday, November 13, 2023. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss third quarter financial results. Webcast Information: Interested parties may join the webcast via the Investors section of the Astria website, www.astriatx.com, or with the following link: https://lifescievents.com/event/astria-2/. Please connect to the webca

-- Differentiated Preclinical Lead Candidate STAR-0310 to be Developed as a Potential Best-in-Class Long-Acting Treatment for Atopic Dermatitis – -- Conference Call and Webcast to be Held on October 12, 2023 at 8:30am ET -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has entered into a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential treatment of atopic dermatitis (AD) and potentially for other allergic and immunological diseases. Astria plans to develop the lead candidate, called STAR-03

-- ALPHA-STAR Phase 1b/2 Trial in People with HAE Underway with Initial Proof-of-Concept Results Anticipated Mid-2024 -- -- Phase 1a Results Support STAR-0215's Target Profile as a Long-Acting Plasma Kallikrein Inhibitor with Estimated Half-Life of up to 117 Days -- -- Ended 4Q 2022 with Cash, Cash Equivalents, and Short-term Investments of $226M, Expected Cash Runway Through H1 2025 -- -- Webcast Today at 8:30am ET -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for t

Astria Therapeutics, Inc. (NASDAQ:ATXS) a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, will report fourth quarter/full year 2022 financial results before the Nasdaq Global Market open on Wednesday, March 22, 2023. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss fourth quarter and full year 2022 financial results. Webcast Information: Interested parties may join the webcast via the Investors section of the Astria website, www.astriatx.

-- Preliminary Results from Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects Expected by Year-End 2022 -- -- Phase 1a Results Expected to Inform on STAR-0215's Profile to Prevent Attacks in Hereditary Angioedema -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update. "We are on track to report preliminary results from our Phase 1a trial of STAR-0215 by the end of this year. The trial is assessing safety and

-- FDA Cleared IND Application for STAR-0215 for the Treatment of Hereditary Angioedema -- -- Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects Initiated, Preliminary Results Anticipated by Year-End 2022 -- -- Company to Host a Virtual R&D Day on September 30 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update. "We are thrilled to announce that we have initiated dosing in our Phase 1a trial of STAR-0215 whic

-- On Track to File IND Application for STAR-0215 Mid-Year -- -- Initial Phase 1a Clinical Results Anticipated by Year End 2022 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. "We are excited to advance STAR-0215 to the clinic this year with the planned initiation of our Phase 1a study," said Jill C. Milne, Ph.D., Chief Executive Officer of Astria. "STAR-0215 was created with a clear vision aim

-- STAR-0215, in Development to Treat HAE, on Track for Initial Phase 1 Clinical Results Expected by Year End 2022 -- -- New Preclinical Data on STAR-0215 Demonstrating High Potency and Extended Plasma Half-Life -- -- Findings on Burdens of Disease and Treatment in HAE Support Substantial Need to Decrease Patient Burden -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. "Our new company name, Astria, embodies our commitment to put patients first in all that we do. Astria originates fro

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), will report third quarter 2021 financial results before the Nasdaq Global Market open on Wednesday, November 10, 2021. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss third quarter financial results. Conference Call Dial-In Information: Participant Toll-Free Dial-In Number: (877) 388-2733 Participant International Dial-In Number: (541) 797-2984 Passcode: 3606309 Please specify to the operator that you